Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 9/20 | 0.81 |
| ▸ | CA2 | P00918 | 3/20 | 0.64 |
| ▸ | CA9 | Q16790 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.61 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | GMNN | O75496 | 1/20 | 0.61 |
| ▸ | SHBG | P04278 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2457836 | 1.00 | STS (0.81) | STSCA2CA9CYP1A2CYP3A4 | |
| SCHEMBL2457838 | 1.00 | STS (0.81) | STSCA2CA9CYP1A2CYP3A4 | |
| SCHEMBL2453754 | 1.00 | STS (0.81) | STSCA2CA9CYP1A2CYP3A4 | |
| SCHEMBL14070737 | 0.90 | STS (0.72) | STSCA2CA9 | |
| SCHEMBL2451744 | 0.90 | STS (1.00) | STSCA2CA9CYP1A2CYP3A4 | |
| SCHEMBL2452253 | 0.90 | STS (1.00) | STSCA2CA9CYP1A2CYP3A4 | |
| SCHEMBL2451742 | 0.90 | STS (1.00) | STSCA2CA9CYP1A2CYP3A4 | |
| SCHEMBL2452248 | 0.90 | STS (1.00) | STSCA2CA9CYP1A2CYP3A4 | |
| SCHEMBL7085806 | 0.89 | STS (0.76) | STSCA2CA9CYP1A2CYP3A4 | |
| SCHEMBL7079725 | 0.89 | STS (0.76) | STSCA2CA9CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100544-A1 | Inhibiting tubulin polymerization; treating prostate and breast cancer | SCHERING AG (DE) | 2003-05-29 | — | — | US | claimed |
| US-8026229-B2 | Inhibiting tubulin polymerization; treating prostate and breast cancer | STERIX LIMITED (GB) | 2011-09-27 | — | — | US | disclosed |
| US-20030100544-A1 | Inhibiting tubulin polymerization; treating prostate and breast cancer | SCHERING AG (DE) | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100544-A1 | Inhibiting tubulin polymerization; treating prostate and breast cancer | TUBA1C, TUBB1, NR5A1 | STS 399/4885CA2 3298/4885CA9 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.